# Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

> **NCT00807001** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 41 (actual)

## Conditions studied

- Chronic Hepatitis C (HCV)

## Interventions

- **DRUG:** IDX184

## Key facts

- **NCT ID:** NCT00807001
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807001, "Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00807001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*